Pipeline — registered trials by phase
No registered trials in this stage.
Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults
— · Healthy Volunteer · Completed · est. 2016-01-06
A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects
— · Symptomatic Obstructive Hypertrophic Cardiomyopathy, Healthy Subjects · Completed · est. 2020-01-03
Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval
— · Healthy Participants · Completed · est. 2023-11-14
A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants
— · Healthy Participants · Completed · est. 2024-11-20
A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers
— · Heart Failure · Completed · est. 2006-04
Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults
— · QT Intervals Changes, QTc Intervals Changes · Completed · est. 2020-03-04
Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency
— · Heart Failure · Completed · est. 2013-01
A Study of CK-1827452 Infusion in Stable Heart Failure
— · Heart Failure · Completed · est. 2009-02
A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma
— · Non-Hodgkin's Lymphoma, Hodgkin's Disease · Completed · est. 2010-07
Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction
— · Heart Failure With Reduced Ejection Fraction · Completed · est. 2017-04-06
A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
— · Amyotrophic Lateral Sclerosis · Completed · est. 2010-11
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
— · Amyotrophic Lateral Sclerosis · Completed · est. 2014-03
PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina
— · Heart Failure, Myocardial Ischemia, Angina Pectoris · Completed · est. 2008-11
A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
— · Amyotrophic Lateral Sclerosis · Completed · est. 2019-03-07
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
— · Amyotrophic Lateral Sclerosis · Completed · est. 2012-03
Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy
— · Hypertrophic Cardiomyopathy (HCM) · Completed · est. 2023-02-28
A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication
— · Intermittent Claudication, Peripheral Artery Disease · Completed · est. 2011-03
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
— · Amyotrophic Lateral Sclerosis · Completed · est. 2012-03
COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure
— · Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure · Completed · est. 2015-07-22
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
— · Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) · Recruiting · est. 2026-09
Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure
— · Heart Failure · Completed · est. 2009-10
A Study of CK-2127107 in Patients With Spinal Muscular Atrophy
— · Spinal Muscular Atrophy · Completed · est. 2018-05-31
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
— · Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy · Active Not Recruiting · est. 2030-01
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
— · Amyotrophic Lateral Sclerosis · Completed · est. 2017-03-09
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
— · Amyotrophic Lateral Sclerosis (ALS) · Completed · est. 2018-10-26
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
— · Obstructive Hypertrophic Cardiomyopathy (oHCM) · Completed · est. 2025-02-28
Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure
— · Heart Failure With Reduced Ejection Fraction · Completed · est. 2021-11-08
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
— · Symptomatic Hypertrophic Cardiomyopathy (HCM) · Enrolling By Invitation · est. 2028-03
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction
— · Heart Failure · Completed · est. 2020-09-14
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
— · Obstructive Hypertrophic Cardiomyopathy (oHCM) · Completed · est. 2023-11-10
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
— · Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy · Active Not Recruiting · est. 2026-08-31
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
— · Heart Failure, Heart Failure With Reduced Ejection Fraction · Recruiting · est. 2027-09
MyqorzoAficamten
Source: ClinicalTrials.gov (trials where Cytokinetics is lead sponsor; 33 active or completed) and Drugs@FDA (1 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-08-28Current report (material event)
- SCHEDULE 13G/A2026-08-13SCHEDULE 13G/A
- 8-K2026-08-13Current report (material event)
- 10-Q2026-08-06Quarterly report
- 8-K2026-08-06Current report (material event)
- SCHEDULE 13G/A2026-07-08SCHEDULE 13G/A
- S-82026-05-27Employee stock plan
- 8-K2026-05-27Current report (material event)
- 8-K2026-05-08Current report (material event)
- 424B52026-05-07Prospectus (offering)
- SCHEDULE 13G/A2026-05-06SCHEDULE 13G/A
- 424B52026-05-05Prospectus (offering)
- 8-K2026-05-05Current report (material event)
- 10-Q2026-05-05Quarterly report
- 8-K2026-05-05Current report (material event)
- SCHEDULE 13G2026-04-29SCHEDULE 13G
- ARS2026-04-17Annual report to holders
- DEF 14A2026-04-17Proxy statement
- SCHEDULE 13G/A2026-03-26SCHEDULE 13G/A
- S-82026-02-26Employee stock plan
- 10-K2026-02-26Annual report
- 8-K2026-02-24Current report (material event)
- SCHEDULE 13G/A2026-02-17SCHEDULE 13G/A
- 8-K2026-02-17Current report (material event)
- 8-K2025-12-19Current report (material event)
- 8-K2025-12-12Current report (material event)
- 8-K2025-11-14Current report (material event)
- SCHEDULE 13G/A2025-11-14SCHEDULE 13G/A
- SCHEDULE 13G2025-11-10SCHEDULE 13G
- 10-Q2025-11-05Quarterly report
- 8-K2025-11-05Current report (material event)
- 8-K2025-09-22Current report (material event)
- 8-K2025-09-16Current report (material event)
- 8-K/A2025-09-08Current report (amended)
- 8-K2025-09-03Current report (material event)
- 8-K2025-09-02Current report (material event)
- 8-K2025-08-20Current report (material event)
- SCHEDULE 13G/A2025-08-14SCHEDULE 13G/A
- UPLOAD2025-08-13UPLOAD
- CORRESP2025-08-08CORRESP
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.